Literature DB >> 24750685

Aplastic anemia: possible associations with lymphoproliferative neoplasms.

A Tzankov1, M Medinger.   

Abstract

Aplastic anemia (AA) may precede, co-occur, or follow a lymphoproliferative neoplasm. The best molecularly clarified scenario is that of concurrent AA and unsuspected (occult) T-cell large granular lymphocyte leukemia. Several reported cases of AA and concurrent small B-cell lymphomas/leukemias and Hodgkin lymphomas suggest also a possible link to simultaneous or preceding AA that might be sought in an antineoplastic immunological attempt to 'eradicate' the underlying malignant clone. The 'immuno-deregulatory' potential and the direct cytotoxicity of regimens used for lymphoma therapy might be able to trigger AA in cases evolving after lymphoma treatment too. Alternative explanations of AA associated with lymphoproliferative disorders might be particular (immuno-)genetic patient backgrounds predisposing to both AA and lymphoid neoplasms or exposures to environmental factors, increasing the risk for both diseases. Finally, the most common causal relationship of AA and lymphoma is that of immunosuppression- or allogeneous hematopoietic stem cell transplantation-associated posttransplantational lymphoproliferative disorders in AA patients, who are treated in the respective manner. As all above scenarios are differently (specifically) therapeutically approachable and accompanied by diverse outcomes, they should be actively sought for and diagnosed as precisely as possible. This review summarizes the current knowledge on associations between AA and lymphoproliferative neoplasms.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  Aplastic anemia; autoimmunity; lymphoproliferative neoplasms

Mesh:

Year:  2014        PMID: 24750685     DOI: 10.1111/ijlh.12224

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  6 in total

1.  Calcitriol-mediated reduction in IFN-γ output in T cell large granular lymphocytic leukemia requires vitamin D receptor upregulation.

Authors:  Paige M Kulling; Kristine C Olson; Thomas L Olson; Cait E Hamele; Kathryn N Carter; David J Feith; Thomas P Loughran
Journal:  J Steroid Biochem Mol Biol       Date:  2017-07-20       Impact factor: 4.292

Review 2.  Vitamin D in hematological disorders and malignancies.

Authors:  Paige M Kulling; Kristine C Olson; Thomas L Olson; David J Feith; Thomas P Loughran
Journal:  Eur J Haematol       Date:  2016-11-21       Impact factor: 2.997

Review 3.  Concurrent Epstein-Barr virus associated NK/T cell lymphoma after immunosuppressive therapy for aplastic anemia: report of a case and review of literature.

Authors:  Guangli Yin; Ying Ni; Zhengrui Xiao; Guangsheng He; Kourong Miao
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

4.  Hodgkin lymphoma patients have an increased incidence of idiopathic acquired aplastic anemia.

Authors:  Taylor Linaburg; Adam R Davis; Noelle V Frey; Muhammad R Khawaja; Daniel J Landsburg; Stephen J Schuster; Jakub Svoboda; Yimei Li; Yuliya Borovskiy; Timothy S Olson; Adam Bagg; Elizabeth O Hexner; Daria V Babushok
Journal:  PLoS One       Date:  2019-04-05       Impact factor: 3.240

5.  Severe Aplastic Anemia as First Manifestation of Classical Hodgkin Lymphoma.

Authors:  Cláudia L Pedrosa; Patrícia Rosinha; Patrícia Seabra; Gisela Ferreira; Cláudia Rosado; Luísa Regadas; Cláudia Casais; Jorge Coutinho
Journal:  Case Rep Hematol       Date:  2021-02-09

Review 6.  Telomere-regulating genes and the telomere interactome in familial cancers.

Authors:  Carla Daniela Robles-Espinoza; Martin del Castillo Velasco-Herrera; Nicholas K Hayward; David J Adams
Journal:  Mol Cancer Res       Date:  2014-09-22       Impact factor: 5.852

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.